Latest News about TAK
Recent news which mentions TAK
7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen
October 21, 2021
From Motley Fool
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
October 20, 2021
From Benzinga
From Benzinga
From Benzinga
Calithera Buys Two Oncology Candidates From Takeda For $45M
October 19, 2021
From Benzinga
From Benzinga
3 Biotech Stocks You Can Buy and Hold for the Next Decade
October 13, 2021
From Motley Fool
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
From Benzinga
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
October 06, 2021
Tickers
TAK
From Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 06, 2021
From Benzinga
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
October 06, 2021
Tickers
TAK
From Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 06, 2021
From Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
From Benzinga
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
October 06, 2021
From Benzinga
Why Novavax Sank by Nearly 5% on Tuesday
October 05, 2021
From Motley Fool
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
From Benzinga
This Healthcare Company Is Using AI to Develop Drugs
October 03, 2021
From Motley Fool
From Benzinga
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
Takeda In-Licenses Hunter Syndrome Candidate
September 30, 2021
From Benzinga
3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
September 30, 2021
From Motley Fool
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
September 24, 2021
From Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
September 21, 2021
From Benzinga
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
September 21, 2021
From Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
From Benzinga
From Benzinga
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
September 16, 2021
From Benzinga
Novavax Has More Room to Run as the Vaccination Push Carries On
September 14, 2021
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.